John Vaughn, MD, MS
@johnvaughnmd
Followers
584
Following
1K
Media
7
Statuses
485
Lymphoma and transplant specialist at @NYULangone
Mineola, NY
Joined November 2011
RT @JAMANetworkOpen: This survey study found that 21.2% of US medical students experience food insecurity, nearly double the national house….
0
8
0
RT @tobyeyre82: Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis ht….
ashpublications.org
Key Points. POD post-CAR-T for R/R MCL is associated with short OS and time from CAR-T infusion to POD, predicted inferior OS in this settingBispecific ant
0
16
0
RT @NEJM: In a patient with pathogenic ZAP70 mutations and HPV19-integrated SCC, restoring T-cell receptor signaling by stem-cell transplan….
0
5
0
RT @richardbuka: 1/ Pleased to have been involved in this study in @BrJHaem that looks at secondary & idiopathic polycythaemia. This is not….
0
24
0
RT @BrianShafferMD: Updated allogeneic stem cell donor guidelines from the CIBMTR/NMDP. A collaborative effort with many wonderful colleagu….
0
4
0
RT @michaelwangmd: Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma | Journal of Clinical Oncology. Hot from pre….
ascopubs.org
PURPOSEThe combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS),...
0
11
0
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial
ashpublications.org
Key PointsSalvage autologous transplant vs lenalidomide/dexamethasone offers no significant survival benefit in RRMM.Time to progression after a frontline
0
0
6
RT @GuiperiniMD: Real world Burkitt Lymphoma is different from clinical trials, especially in LMIC. Data from Colômbia confirms a higher m….
0
1
0
Should every patient with newly diagnosed TP53 mutated MCL be treated with the BOVen regimen, assuming no financial or other barriers to treatment? #lymsm.
1
0
4
Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma
ashpublications.org
Key PointsDespite having relatively favorable disease kinetics, patients with relapsed/refractory BL who receive CAR T cells have poor outcomes.Future tria
0
0
3
It was a pleasure to contribute to this study.
Many institutions disallow or limit ICIs for hospitalized pts w/cancer because they have to eat the cost. But what about clinical benefits? Our group examined clinical outcomes of pts treated with inpatient ICIs at 5 large academic institutions.
0
0
4
RT @VincentRK: If you have a good presentation at #ASH24 that you would like considered for publication in @BloodCancerJnl .@NaturePortfol….
0
17
0
Happy to share this new study out in @BloodCancerJnl, coauthored by @NEpperla.
nature.com
Blood Cancer Journal - A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study
0
4
8
